Absci Corporation (ABSI) vs Intellia Therapeutics, Inc. (NTLA)
Absci Corporation and Intellia Therapeutics, Inc. are both Biotechnology companies. Absci Corporation and Intellia Therapeutics, Inc. are of similar size ($1.8B and $1.7B). Intellia Therapeutics, Inc. grew revenue faster over the last twelve months: 12.6% against −62.3%. Intellia Therapeutics, Inc. has the higher net margin (−672.2% vs −7,756.4%) and the higher return on invested capital (−91.3% vs −174.7%). Across the 17 metrics below, Intellia Therapeutics, Inc. leads on 14 and Absci Corporation on 3.
Valuation
Profitability
| Metric | ABSI | NTLA | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (8,084.50%) | (711.66%) | 0.00% |
| Net margin | (7,756.37%) | (672.16%) | 0.00% |
| Free cash flow margin | (6,969.83%) | (585.82%) | 0.00% |
| Return on equity | (57.72%) | (55.44%) | (57.72%) |
| Return on assets | (50.57%) | (45.55%) | (49.22%) |
| Return on invested capital | (174.74%) | (91.28%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack